Ischemia modified albumin increase indicating cardiac damage after experimental subarachnoid hemorrhage

BMC Neuroscience

Bektaş Açıkgöz⁵  Çağatay Büyükuysal³  İshak Özel Tekin⁴  Murat Can¹  Figen Barut²  Nurullah Edebali⁵  Şerefden Açıkgöz¹ 

[1] Department of Biochemistry, Faculty of Medicine, Bülent Ecevit University (Formerly, Zonguldak Karaelmas University), 67630, Esenköy, Kozlu, Zonguldak, Turkey;Department of Pathologia, Faculty of Medicine, Bülent Ecevit University (Formerly, Zonguldak Karaelmas University), Zonguldak, Turkey;Department of Biostatistics, Faculty of Medicine, Bülent Ecevit University (Formerly, Zonguldak Karaelmas University), Zonguldak, Turkey;Department of Immunologia, Faculty of Medicine, Bülent Ecevit University (Formerly, Zonguldak Karaelmas University), Zonguldak, Turkey;Department of Neurosurgery, Faculty of Medicine, Bülent Ecevit University (Formerly, Zonguldak Karaelmas University), Zonguldak, Turkey

关键词: Experimental subarachnoid hemorrhage;    Cardiac damage;    Ischemia modified albumin;   

Others  :  1092164
DOI  :  10.1186/1471-2202-15-33

 received in 2013-04-06, accepted in 2014-02-12,  发布年份 2014

【 摘 要 】

Background

Cardiac complications are often developed after subarachnoid hemorrhage (SAH) and may cause sudden death of the patient. There are reports in the literature addressing ischemia modified albumin (IMA) as an early and useful marker in the diagnosis of ischemic heart events. The aim of this study is to evaluate serum IMA by using the albumin cobalt binding (ACB) test in the first, second, and seventh days of experimental SAH in rats.

Twenty-eight Wistar albino rats were divided into four groups each consisting of seven animals. These were classified as control group, 1st, 2nd and 7th day SAH groups. SAH was done by transclival basilar artery puncture. Blood samples were collected under anesthesia from the left ventricles of the heart using the cardiac puncture method for IMA measurement. Histopathological examinations were performed on the heart and lung tissues. Albumin with by colorimetric, creatine kinase (CK), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) were determined on an automatic analyser using the enzymatic method. IMA using by ACB test was detected with spectrophotometer.

Results

Serum IMA (p = 0.044) in seventh day of SAH were higher compared to the control group. Total injury scores of heart and lung tissue, also myocytolysis at day 7 were significantly higher than control group (p = 0.001, p = 0.001, p = 0.001), day 1 (p = 0.001, p = 0.001, p = 0.001) and day 2 (p = 0.001, p = 0.007, p = 0.001). A positive correlation between IMA - myocytolysis (r = 0.48, p = 0.008), and between IMA – heart tissue total injury score (r = 0.41, p = 0.029) was found.

Conclusion

The results revealed that increased serum IMA may be related to myocardial stress after SAH.

【 授权许可】

   
2014 Açıkgöz et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Tung P, Kopelnik A, Banki N, Ong K, Ko N, Lawton MT, Gress D, Drew B, Foster E, Parmley W, Zaroff J: Predictors of neurocardiogenic injury after subarachnoid hemorrhage. Stroke 2004, 35:548-551.
• [2]Lee VH, Oh JK, Mulvagh SL, Wijdicks EF: Mechanisms in neurogenic stress cardiomyopathy after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2006, 5:243-249.
• [3]Doshi R, Neil-Dwyer G: Hypothalamic and myocardial lesions after subarachnoid hemorrhage. J Neurol Neurosurg Psychiatry 1977, 40:821-826.
• [4]Masuda T, Sato K, Yamamoto S, Matsuyama N, Shimohama T, Matsunaga A, Obuchi S, Shiba Y, Shimizu S, Izumi T: Sympathetic nervous activity and myocardial damage immediately after subarachnoid hemorrhage in a unique animal model. Stroke 2002, 33:1671-1676.
• [5]Sato K, Masuda T, Izumi T: Subarachnoid hemorrhage and myocardial damage clinical and experimental studies. Jpn Heart J 1999, 40:683-701.
• [6]Mertes PM, Carteaux JP, Jaboin Y, Pinelli G, el Abassi K, Dopff C, Atkinson J, Villemot JP, Burlet C, Boulange M: Estimation of myocardial interstitial norepinephrine release after brain death using cardiac microdialysis. Transplantation 1994, 57:371-377.
• [7]Hravnak M, Frangiskakis JM, Crago EA, Chang Y, Tanabe M, Gorcsan J 3rd, Horowitz MB: Elevated cardiac troponin I and relationship to persistence of electrocardiographic and echocardiographic abnormalities after aneurysmal subarachnoid hemorrhage. Stroke 2009, 40:3478-3484.
• [8]Lacy PS, Earle AM: A small animal model for electrocardiographic abnormalities observed after an experimental subarachnoid hemorrhage. Stroke 1983, 14:371-377.
• [9]Elrifai AM, Bailes JE, Shih SR, Dianzumba S, Brillman J: Characterization of the cardiac effects of acute subarachnoid hemorrhage in dogs. Stroke 1996, 27:737-742.
• [10]Franco C, Khaled B, Afonso L, Raufi M: Acute subarachnoid hemorrhage and cardiac abnormalities: takotsubo cardiomyopathy or neurogenic stunned myocardium? A case report. Cases J 2010, 3:81. BioMed Central Full Text
• [11]Zaroff JG, Rordorf GA, Titus JS, Newell JB, Nowak NJ, Torchiana DF, Aretz HT, Picard MH, Macdonald RL: Regional myocardial perfusion after experimental subarachnoid hemorrhage. Stroke 2000, 31:1136-1143.
• [12]Schievink WI, Wijdicks EF, Parisi JE, Piepgras DG, Whisnant JP: Sudden death from aneurysmal subarachnoid hemorrhage. Neurology 1995, 45:871-874.
• [13]Stevens RD, Nyquist PA: The systemic implications of aneurysmal subarachnoid hemorrhage. J Neurol Sci 2007, 261:143-156.
• [14]Sugiura M, Yozawa Y, Kubo O, Kitamura K, Kimata S, Hagiwara H, Joshita H: Myocardial damage (myocytolysis) caused by subarachnoid hemorrhage. No To Shinkei 1985, 37:1155-1161.
• [15]Parekh N, Venkatesh B, Cross D, Leditschke A, Atherton J, Miles W, Winning A, Clague A, Rickard C: Cardiac troponin I predicts myocardial dysfunction in aneurysmal subarachnoid hemorrhage. J Am Coll Cardiol 2000, 36:1328-1335.
• [16]Sakr YL, Ghosn I, Vincent JL: Cardiac manifestations after subarachnoid hemorrhage: a systematic review of the literature. Prog Cardiovasc Dis 2002, 45:67-80.
• [17]Fabinyi G, Hunt D, McKinley L: Myocardial creatine kinase isoenzyme in serum after subarachnoid hemorrhage. J Neurol Neurosurg Psychiatry 1977, 40:818-820.
• [18]Storrow AB, Gibler WB: Chest pain centers: diagnosis of acute coronary syndromes. Ann Emerg Med 2000, 35:449-461.
• [19]Bar‒Or D, Lau E, Winkler JV: A novel assay for cobalt‒albumin binding and its potential as a marker for myocardial ischemia a preliminary report. J Emerg Med 2000, 19:311-315.
• [20]Lippi G, Montagnana M, Guidi GC: Albumin cobalt binding and ischemia modified albumin generation: an endogenous response to ischemia? Int J Cardiol 2006, 108:410-411.
• [21]Bar-Or D, Winkler JV, Vanbenthuysen K, Harris L, Lau E, Hetzel FW: Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty: a preliminary comparison to creatine kinase-MB, myoglobin, and troponin I. Am Heart J 2001, 141:985-991.
• [22]Immanuel S, Sanjaya AI: Albumin cobalt binding (ACB) test: its role as a novel marker of acute coronary syndrome. Acta Med Indones 2006, 38:92-96.
• [23]Gunduz A, Turedi S, Mentese A, Altunayoglu V, Turan I, Karahan SC, Topbas M, Aydin M, Eraydin I, Akcan B: Ischemia-modified albumin levels in cerebrovascular accidents. Am J Emerg Med 2008, 26:874-878.
• [24]Barry KJ, Gogjian MA, Stein BM: Small animal model for investigation of subarachnoid hemorrhage and cerebral vasospasm. Stroke 1979, 10:538-541.
• [25]Van der Bilt IA, Hasan D, Vandertop WP, Wilde AA, Algra A, Visser FC, Rinkel GJ: Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: a meta-analysis. Neurology 2009, 72:635-642.
• [26]Szabo MD, Crosby G, Hurford WE, Strauss HW: Myocardial perfusion following acute subarachnoid hemorrhage in patients with an abnormal electrocardiogram. Anesth Analg 1993, 76:253-258.
• [27]Yuki K, Kodama Y, Onda J, Emoto K, Morimoto T, Uozumi T: Coronary vasospasm following subarachnoid hemorrhage as a cause of stunned myocardium. Case report J Neurosurg 1991, 75:308-311.
• [28]Sinha MK, Roy D, Gaze DC, Collinson PO, Kaski JC: Role of “Ischemia modified albumin”, a new biochemical marker of myocardial ischaemia, in the early diagnosis of acute coronary syndromes. Emerg Med J 2004, 21:29-34.
• [29]Turillazzi E, Baroldi G, Silver MD, Parolini M, Pomara C, Fineschi V: A systematic study of a myocardial lesion: colliquative myocytolysis. Int J Cardiol 2005, 104:152-157.
• [30]Turedi S, Gunduz A, Mentese A, Karahan SC, Yilmaz SE, Eroglu O, Nuhoglu I, Turan I, Topbas M: Value of ischemia-modified albumin in the diagnosis of pulmonary embolism. Am J Emerg Med 2007, 25:770-773.
• [31]Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J: Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 2004, 50:1063-1065.
• [32]Roy D, Quiles J, Sharma R, Sinha M, Avanzas P, Gaze D, Kaski JC: Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem 2004, 50:1656-1660.
• [33]Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM: Release characteristics of cardiac biomarkers and ischemia-modified albumin as measured by the albumin cobalt-binding test after a marathon race. Clin Chem 2002, 48:1097-1100.
• [34]Han K, Jia N, Yang L, Min LQ: Correlation between ischemia-modified albumin and lipid levels in patients with acute cerebrovascular disease. Mol Med Rep 2012, 6:621-624.
• [35]Falkensammer J, Stojakovic T, Huber K, Hammerer-Lercher A, Gruber I, Scharnagl H, Fraedrich G, Santner W, Schocke M, Greiner A: Serum levels of ischemia-modified albumin in healthy volunteers after exercise-induced calf-muscle ischemia. Clin Chem Lab Med 2007, 45:535-540.
• [36]Sbarouni E, Georgiadou P, Kremastinos DT, Voudris V: Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J Cardiol 2008, 49:260-266.